317. Deputy Ken O'Flynn asked the Minister for Health to outline the policy or decision framework used by the Health Service Executive when considering prevention-based outcomes, including reductions in the future incidence of type 2 diabetes and cardiovascular disease, in medicines reimbursement decisions under the Health (Pricing and Supply of Medical Goods) Act 2013; and whether the Department has issued, or inten…
Parliamentary questions
Questions
TDs ask ministers questions to get answers on the record, most of them in writing. Here is every one asked in the 34th Dáil, by the department it went to and the subject heading it was filed under. How questions work
Browse the questions
Showing questions under the heading Medicinal Products.
1,228 questions match, newest first.
318. Deputy Ken O'Flynn asked the Minister for Health whether her Department has undertaken or commissioned any assessment of the equity implications of current access arrangements for GLP-1 receptor agonist medicines for obesity or weight management, including the extent to which access is determined by capacity to pay out of pocket rather than clinical need; and whether the forthcoming national obesity strategy wil…
320. Deputy Ken O'Flynn asked the Minister for Health the current policy position of her Department on whether GLP-1 receptor agonist medicines for obesity or weight management should be eligible for reimbursement under the Drugs Payment Scheme, subject to health technology assessment and clinical governance; whether any policy review is under way in the context of the development of the new national obesity strategy…
321. Deputy Ken O'Flynn asked the Minister for Health whether the national obesity strategy currently in development will explicitly address the role of pharmacological treatment for obesity, including eligibility, reimbursement pathways, and equity of access; and whether she will outline how medicines policy is being aligned with the objectives of that strategy. [10660/26]
344. Deputy David Cullinane asked the Minister for Health the number and the details of medications and medical products approved for reimbursement, but which received a recommendation to not consider the product for recommendation from an agency (details supplied), in tabular form. [10723/26]
345. Deputy David Cullinane asked the Minister for Health the reason pluvicto was not approved for reimbursement but luthathera received approval; and if she will make a statement on the matter. [10724/26]
1135. Deputy Aindrias Moynihan asked the Minister for Health when a NCPE re-commenced assessment will be completed (details supplied); and if she will make a statement on the matter. [10188/26]
1159. Deputy Shane Moynihan asked the Minister for Health for an update on the accessibility of Welireg (belzutifan) for patients with von Hippel-Lindau disease; and if she will make a statement on the matter. [10252/26]
1190. Deputy Pádraig Rice asked the Minister for Health the current reimbursement arrangements in place for GLP-1 medications; to identify the products currently available under each scheme and the criteria for access; if there are plans to expand access; if further products are undergoing pricing and reimbursement assessment; if so, the status of that work; and if she will make a statement on the matter. [10332/26]
1204. Deputy Mark Ward asked the Minister for Health if welireg is available to public HSE patients with von Hippel-Lindau disease; the way they can access this treatment; the alternative treatments that are offered through the HSE; and if she will make a statement on the matter. [10417/26]
984. Deputy Mairéad Farrell asked the Minister for Health the steps she has taken to ensure urgent access to Welireg (belzutifan) for a young adult with von Hippel-Lindau disease; whether compassionate or exceptional access mechanisms are available while national reimbursement processes are ongoing; the safeguards currently in place to protect such patients from avoidable permanent harm during administrative delays; …
986. Deputy Paula Butterly asked the Minister for Health the measures being taken to ensure urgent access to Welireg (belzutifan) for a young adult with von Hippel–Lindau disease, in circumstances where clinicians warn that any delay risks irreversible neurological and functional decline; if compassionate or exceptional access pathways are available pending completion of national reimbursement processes; and the safe…
1020. Deputy Ken O'Flynn asked the Minister for Health whether her Department or the HSE has undertaken, commissioned, or reviewed any health economic or cost-benefit analysis on the use of GLP-1 receptor agonist medicines, including tirzepatide and semaglutide, for obesity treatment and the prevention of type 2 diabetes; if so, the details and outcomes of any such analysis; and if not, whether she intends to commiss…
1021. Deputy Ken O'Flynn asked the Minister for Health the current policy position of her Department regarding the reimbursement of GLP-1 receptor agonist medicines under the Drugs Payment Scheme; whether any review is under way to consider broader eligibility criteria; and the expected timeline for any decision on changes to reimbursement policy. [7677/26]
1022. Deputy Ken O'Flynn asked the Minister for Health whether her Department has assessed the potential impact of GLP-1 receptor agonist medicines on reducing the future incidence of type 2 diabetes, cardiovascular disease, and associated complications; whether such preventative outcomes are factored into medicines reimbursement decisions; and if she will outline how prevention-based savings are weighted in funding …
1023. Deputy Ken O'Flynn asked the Minister for Health what consideration has been given to the equity implications of high out-of-pocket costs for GLP-1 receptor agonist medicines; whether the Department has examined the risk of access being determined by ability to pay rather than clinical need; and if she will outline any measures under consideration to address this issue. [7679/26]
1037. Deputy Carol Nolan asked the Minister for Health if she will intervene to support the case of a person (details supplied) in urgent need of life-saving medication; and if she will make a statement on the matter. [7717/26]
1047. Deputy Ann Graves asked the Minister for Health the steps which are being taken to ensure urgent access to Welireg (belzutifan) for a young adult with von Hippel-Lindau disease where clinicians advise that delay risks irreversible loss of neurological and functional ability; whether compassionate or exceptional access mechanisms are available while national reimbursement processes are ongoing; and the safeguard…
1053. Deputy Eamon Scanlon asked the Minister for Health the steps being taken to ensure urgent access to Welireg (belzutifan) for a young adult with von Hippel-Lindau disease where clinicians advise that delay risks irreversible loss of neurological and functional ability; whether compassionate or exceptional access mechanisms are available while national reimbursement processes are ongoing; the safeguards which are…
1058. Deputy Mark Wall asked the Minister for Health if she will provide access to a medicine for the urgent case of a person (details supplied). [7780/26]
1059. Deputy Mark Wall asked the Minister for Health the steps being taken to ensure urgent access to Welireg (belzutifan) for a young adult with Von Hippel-Lindau disease where clinicians advise that delay risks irreversible loss of neurological and functional ability; and the safeguards currently in place to protect such patients from avoidable permanent harm during administrative delays. [7781/26]
1062. Deputy John Connolly asked the Minister for Health the steps being taken to ensure access to Welireg (belzutifan) for patients with Von Hippel–Lindau disease whose treating clinicians advise that delay risks irreversible neurological and functional decline; if compassionate or exceptional access mechanisms are available; and if she will make a statement on the matter. [7800/26]
1081. Deputy Pádraig O'Sullivan asked the Minister for Health the reason low-dose atropine (0.05%) eye drops for myopia control are difficult to obtain or totally unavailable (details supplied); if she will make provision for this medicine to be sourced for children who need them; and if she will make a statement on the matter. [7918/26]
1146. Deputy Grace Boland asked the Minister for Health the status of the proposed national rollout of the iSIMPATHY medication safety programme, which demonstrated improved patient outcomes and cost savings during its HSE pilot; the timeline for national implementation; and if she will make a statement on the matter. [8432/26]
1147. Deputy Grace Boland asked the Minister for Health her plans to strengthen national medication safety initiatives in line with the WHO “Medication Without Harm” programme; if she will report on progress in ensuring that every patient has access to clear medication information, including the medicines list recently incorporated into the Health App; and if she will make a statement on the matter. [8433/26]